corporate_fare

Liquidia Technologies Inc.

Address: 419 Davis Drive Suite 100

Sponsor Overview

assignment

Specializations

Pulmonary Hypertension and Interstitial Lung Disease

Research activity is centered on pulmonary hypertension associated with interstitial lung disease (WHO Group 3), with interest in therapies for elevated pulmonary vascular pressure in the setting of chronic fibrotic and inflammatory lung disease. The sponsor’s clinical work reflects a focus on respiratory medicine and pulmonary vascular disease.

PH-ILD
Pulmonary vascular remodeling
Interstitial lung disease

The clinical landscape is directed toward inhaled treatment approaches for symptoms and functional limitation linked to impaired lung circulation and reduced exercise capacity.

Exercise Capacity and Functional Outcomes

Clinical interest includes outcomes related to exercise tolerance and daily physical function, with emphasis on the six-minute walk test as a measure of mobility and cardiopulmonary limitation in patients with pulmonary hypertension.

Six-minute walk test
Walk distance
Functional capacity

This area highlights therapeutic attention to improving activity-related performance in people affected by chronic lung and vascular disease.

Inhaled Therapeutics

The sponsor is engaged in research involving inhaled treatment strategies for lung-targeted delivery in pulmonary hypertension, reflecting a therapeutic interest in local airway administration for diseases with both vascular and parenchymal components.

Inhaled therapy
Lung-targeted delivery
Respiratory therapeutics

Its clinical focus aligns with therapies intended for patients whose disease burden is driven by underlying interstitial lung disease and secondary pulmonary vascular impairment.

Trial Name	Country	Status
Efficacy and Safety of Inhaled Treprostinil Liposome in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)	Austria Belgium Czechia France Germany Italy Latvia Poland Portugal Spain	Recruiting